CD19 and neoplasm: Avanzi et al. treated an immunocompetent syngeneic mouse model with murine CD19-targeting CAR T cells constitutively secreting IL-18 and observed enhanced persistence, tumour infiltration, and overall survival compared with CAR only controls [96].